Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems (NYSE: VEEV) announced its participation in two major investor conferences in June 2025. EVP Strategy Paul Shawah will present at the Baird 2025 Global Consumer, Technology & Services Conference in New York on June 3 at 10:50 a.m. ET. CFO Brian Van Wagener will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 4 at 1:20 p.m. CT. Both presentations will be available via webcast on Veeva's investor relations website, with live and archived versions accessible at ir.veeva.com.

Veeva Systems (NYSE: VEEV) has released new insights from its Pulse Field Trends Report highlighting the importance of content effectiveness over content creation in driving treatment adoption. The report reveals that content-driven HCP engagement more than doubles treatment adoption and reduces time between meetings by up to 25%. However, there's a significant gap in execution as field teams share materials in less than half of customer interactions, and nearly 80% of approved content is rarely or never used. While AI can reduce content creation costs by 30-50% and speed production by over 20%, the focus should be on leveraging AI to surface relevant content at the right moment for more effective customer conversations. The report emphasizes that increasing content volume through AI should not overshadow the importance of strategic content deployment and engagement effectiveness.

Veeva Systems reported strong fiscal 2026 Q1 results with total revenues of $759.0M, up 17% YoY. Subscription services revenues grew 19% YoY to $634.8M. The company demonstrated significant profit growth with operating income increasing 51% to $233.7M and net income rising 41% to $228.2M. Notable achievements include surpassing the $3B revenue run rate goal and launching Veeva AI initiative, set for December 2025 release. The company expanded its commercial data offerings with Veeva CRM Pulse in March. Looking ahead, Veeva provided Q2 guidance with expected revenues between $766-769M and updated FY2026 guidance with total revenues projected between $3,090-3,100M.

Veeva Systems (NYSE: VEEV) announced that over 75 biotechnology companies are now using Veeva Basics, their pre-configured and pre-validated software solution for clinical, regulatory, and quality operations. The company has introduced two new applications: Veeva CTMS Basics for clinical trial management and Veeva Submissions Publishing Basics for regulatory submissions.

The rapid adoption indicates a market shift from basic tools to comprehensive solutions that can scale with company growth. Available in North America and Europe, these solutions enable biotechs to deploy industry-leading software within weeks. Built on the Vault Platform, Veeva Basics allows customers to maintain current features and adapt their technology infrastructure as they expand.

Veeva Systems (NYSE: VEEV) has scheduled the release of its fiscal 2026 first quarter financial results for May 28, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted to Veeva's investor relations website at approximately 1:05 p.m. PT. The quarter ended on April 30, 2025, and a webcast replay will be available on the company's website following the live event.

Veeva Systems (NYSE: VEEV) has announced its 2025 Veeva Commercial Summit, scheduled for May 13-14 in Boston. The event will feature keynote speakers from major pharmaceutical companies sharing strategies for unified customer engagement. CEO Peter Gassner will discuss Veeva's initiative to integrate AI into the Vault Platform and applications.

Key presentations include AstraZeneca's analytics standardization, Bayer's customer-centric engagement with Vault CRM, Boehringer Ingelheim's medical insights coordination, and Lilly's content ecosystem integration. Johnson & Johnson and Madrigal will showcase their data foundation implementations. The summit, one of North America's largest industry events for commercial and medical affairs leaders, will also feature emerging biotechs sharing go-to-market strategies.

Veeva Systems has announced Veeva AI, a major initiative adding artificial intelligence capabilities to their Vault Platform and applications. The AI enhancement aims to boost productivity across clinical, regulatory, safety, quality, medical, and commercial sectors through AI Agents and AI Shortcuts.

The platform will feature application-specific AI Agents that understand context, include safeguards, and securely access Veeva data. Users can customize these agents and create new ones for specific needs. AI Shortcuts allow users to set up personal automations for common tasks.

Key features include:

• LLM-agnostic design supporting major language models
• Flexible deployment with Veeva-supplied or customer-specific LLMs
• Secure data handling for each customer
• Simple subscription fee structure

The first release is scheduled for December 2025, with licensing at the Vault level.

Veeva Systems (NYSE: VEEV) has announced SiteVault CTMS, a new clinical trial management system designed to enhance research site efficiency. The system will be integrated with SiteVault eISF and SiteVault eConsent, enabling comprehensive trial management within a single platform.

The solution features bidirectional data flow integration with sponsors using Veeva's Clinical Platform, aimed at reducing manual processes. Notably, SiteVault CTMS will be free for sites managing up to 20 concurrent active studies, representing over 90% of research sites.

The initial release is planned for August 2025, with live demonstrations scheduled during ACRP 2025 in New Orleans (April 24-27).

Veeva Systems (NYSE: VEEV) announced that Indero, formerly Innovaderm Research, has successfully completed its 40th study implementation using Veeva RTSM (Randomization and Trial Supply Management). This milestone demonstrates the successful standardization of Indero's clinical trial operations using Veeva's RTSM platform.

The specialized CRO has leveraged Veeva RTSM's advanced capabilities to enhance operational efficiency, improve process consistency, and streamline trial execution. Eric Hardy, senior director of biometrics at Indero, highlighted that the platform has enabled more efficient processes and better collaboration, ultimately accelerating the path to bringing therapies to market.

The partnership between Indero and Veeva has focused on developing and implementing standardized processes for long-term clinical trial success, with Veeva's enterprise standard RTSM approach contributing to greater efficiency and reliability in study execution.